The study will be conducted in the United States of America.~Eligible healthy participants will be randomized in a 10:2 ratio to receive either AZD3152 or placebo administered IM or IV, across 4 fixed-dose cohorts. Participants will receive a single dose of AZD3152/placebo.~Cohort 1: Dose X of AZD3152 or placebo, as an IM injection Cohort 2: Dose X of AZD3152 or placebo, administered IV Cohort 3: Dose Y of AZD3152 or placebo, as an IM injection Cohort 4: Dose Y of AZD3152 or placebo, administered IV~The study will comprise of:~A Screening Period of maximum 28 days.~A Treatment Period of 1 Day.~A Follow-up Period of 12 months after study intervention (Day 365).
This is a dose exploration study to evaluate the safety and pharmacokinetics (PK) of AZD3152 in healthy adult male and female participants, across different dose levels and routes of administration (ie, Intramuscular [IM] injection and Intravenous [IV] infusion).